IPHA Stock Analysis: Buy, Sell, or Hold?
IPHA - Innate Pharma S.A. ADS
$1.78
-0.04 (-2.20%)
▼
5d:
+0.0%
30d:
-2.2%
90d:
-9.64%
BUY
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Mar 26, 2026
Get Alerted When IPHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IPHA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IPHA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IPHA is currently trading at $1.78, which is considered fair relative to its 30-day fair value range of $1.74 to $1.80.
Technical Outlook: Technically, IPHA is in a downtrend. The price is currently testing key support at $1.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.75 (+223.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IPHA is in a downtrend. The price is currently testing key support at $1.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.75 (+223.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.74 -
$1.80
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 223.0% below Wall St target ($5.75)
Fair Price Analysis
30-Day Fair Range
$1.74 -
$1.80
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$1.74
Resistance Level
$1.89
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.94
Wall Street Target
$5.75
(+223.0%)
Revenue Growth (YoY)
-60.6%
Earnings Growth (YoY)
-74.7%
Last updated: February 04, 2026 9:13 AM ET
Data refreshes hourly during market hours. Next update: 10:13 AM
Data refreshes hourly during market hours. Next update: 10:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
